TY - JOUR
T1 - Development of new method to enrich human iPSC-derived renal progenitors using cell surface markers
AU - Hoshina, Azusa
AU - Kawamoto, Tatsuya
AU - Sueta, Shin Ichi
AU - Mae, Shin Ichi
AU - Araoka, Toshikazu
AU - Tanaka, Hiromi
AU - Sato, Yasunori
AU - Yamagishi, Yukiko
AU - Osafune, Kenji
N1 - Funding Information:
The authors are grateful to Drs. Taro Toyoda, Hirofumi Hitomi, Tatsuyuki Inoue and Hiraku Tsujimoto for their technical supports, helpful suggestions and discussions, Dr. Kanae Mitsunaga for her technical assistance in flow cytometry analysis, Dr. Peter Karagiannis for critically reading the manuscript, Ms. Tomomi Sudo, Kyoko Matsuse and Natsumi Okamoto for their excellent technical assistance and Ms. Erika Moriguchi and Saori Uno for their excellent secretarial assistance. This study was partially supported by the Japan Agency for Medical Research and Development (AMED) through its research grant “Technological Development, Research Center Network for Realization of Regenerative Medicine” to K.O.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Cell therapy using renal progenitors differentiated from human embryonic stem cells (hESCs) or induced pluripotent stem cells (hiPSCs) has the potential to significantly reduce the number of patients receiving dialysis therapy. However, the differentiation cultures may contain undifferentiated or undesired cell types that cause unwanted side effects, such as neoplastic formation, when transplanted into a body. Moreover, the hESCs/iPSCs are often genetically modified in order to isolate the derived renal progenitors, hampering clinical applications. To establish an isolation method for renal progenitors induced from hESCs/iPSCs without genetic modifications, we screened antibodies against cell surface markers. We identified the combination of four markers, CD9-CD140a+CD140b+CD271+, which could enrich OSR1+SIX2+ renal progenitors. Furthermore, these isolated cells ameliorated renal injury in an acute kidney injury (AKI) mouse model when used for cell therapy. These cells could contribute to the development of hiPSC-based cell therapy and disease modeling against kidney diseases.
AB - Cell therapy using renal progenitors differentiated from human embryonic stem cells (hESCs) or induced pluripotent stem cells (hiPSCs) has the potential to significantly reduce the number of patients receiving dialysis therapy. However, the differentiation cultures may contain undifferentiated or undesired cell types that cause unwanted side effects, such as neoplastic formation, when transplanted into a body. Moreover, the hESCs/iPSCs are often genetically modified in order to isolate the derived renal progenitors, hampering clinical applications. To establish an isolation method for renal progenitors induced from hESCs/iPSCs without genetic modifications, we screened antibodies against cell surface markers. We identified the combination of four markers, CD9-CD140a+CD140b+CD271+, which could enrich OSR1+SIX2+ renal progenitors. Furthermore, these isolated cells ameliorated renal injury in an acute kidney injury (AKI) mouse model when used for cell therapy. These cells could contribute to the development of hiPSC-based cell therapy and disease modeling against kidney diseases.
UR - http://www.scopus.com/inward/record.url?scp=85045885195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045885195&partnerID=8YFLogxK
U2 - 10.1038/s41598-018-24714-3
DO - 10.1038/s41598-018-24714-3
M3 - Article
C2 - 29686294
AN - SCOPUS:85045885195
SN - 2045-2322
VL - 8
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 6375
ER -
